AVBP CIK: 1868279

ArriVent BioPharma, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY23
FY24
FY25
FY23 – FY25

Assets

(positive)
Change from FY23 to FY25
millions USD
FY23:
160
FY24:
227
FY25:
333
(positive)
Change from FY23 to FY25
millions USD
FY23:
3.13
FY24:
48.0
FY25:
0.27
Total assets
Change from FY23 to FY25
millions USD
FY23:
163
FY24:
275
FY25:
333

Liabilities & Equity

(negative)
Change from FY23 to FY25
millions USD
FY23:
11.6
FY24:
17.3
FY25:
25.9
(negative)
Change from FY23 to FY25
millions USD
FY23:
0.18
FY24:
0.01
FY25:
0
(positive)
Change from FY23 to FY25
millions USD
FY23:
−153
FY24:
258
FY25:
307
Total liabilities & equity
Change from FY24 to FY25
millions USD
FY23:
–
FY24:
275
FY25:
333

All amounts in millions USD Data source:SEC EDGAR